tirzepatide semaglutide comparison weight loss Forest plot of % mean differences in versus Tirzepatide vs. semaglutide for weight

It was removed from FDA Category 2 effective April 22, 2026, and is scheduled for Pharmacy Compounding Advisory Committee discussion on July 23, 2026

Its also approved to reduce the risk for major cardiovascular events (heart attack, stroke) in adults with type 2 diabetes who also have heart disease

Promptly, especially if it is persistent, worsening, or accompanied by other symptoms

However, head-to-head data comparing the drugs in routine practice remain limited, particularly among people without diabetes or established cardiovascular disease

Without these efforts, the benefits of medication may fade over time, and weight regain can occur quickly once treatment ends